

10/560754

IAP20 Rec'd PCT/PTO 13 DEC 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :  
Takayuki DOI et al. : **Mail Stop: PCT**  
Serial No. NEW : Attorney Docket No. 2005\_1863A  
Filed December 13, 2005 :

PREVENTIVE/REMEDY FOR URINARY DISTURBANCE  
[Corresponding to PCT/JP2004/009486  
Filed June 29, 2004]

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- ☒ each U.S. Patent and U.S. Patent application publication;
- ☐ each reference previously cited in the international application PCT/\_\_\_\_\_; and/or
- ☐ each reference previously cited in prior parent application Serial No. \_\_\_\_\_.

1a. ☒ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, **or**

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

ATTACHMENT C }

**and thus no certification and/or fee is required.**

- 1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) ☐ the certification of paragraph 2 below is provided, **or**  
(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

- 1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

**the certification of paragraph 2 below is provided, and  
the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.**

2. It is hereby certified

- a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or  
b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.


JAP20 Received PTO 13 DEC 2005

4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
  - b. ☐ a foreign patent office search report (in the English language) submitted herewith,
  - c. ☐ the concise explanation contained in the specification of the present application at page,
  - d. ☐ the concise explanation set forth in the attached English language abstract,
  - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☒ A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Takayuki DOI et al.

By



Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/dlk  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
December 13, 2005

## INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: December 13, 2005

ATTY DOCKET NO.  
2005\_1863ASERIAL NO.  
NEWAPPLICANT  
Takayuki DOI et al.FILING DATE  
December 13, 2005

GROUP

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	2002/0177593	11/2002	Ishihara et al.			Corresponds to AE
	AB	5,527,800	6/1996	Goto et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AC	1 466 625	10/2004	EP			
	AD	2001/335576	12/2001	JP			Corresponds to AE Abstract
	AE	2000-169373	6/2000	JP			Abstract
	AF	03/057254	7/2003	WO			Abstract
	AG	7-206854	8/1995	JP			
	AH	0 607 864	9/2003	EP			Corresponds to AG

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AI	T. Nakahara et al., "The role of cholinesterases in rat urinary bladder contractility", Urol. Res., Vol. 31, pp. 223-226, 2003.
	AJ	H. Nagabukuro et al., "Effects of TAK-802, A Novel Acetylcholinesterase Inhibitor, on Distension-Induced Rhythmic Bladder Contractions in Rats and Guinea Pigs", European Journal of Pharmacology, Vol. 285, pp. 299-305, 2004.
	AK	H. Nagabukuro et al., "Effects of TAK-802, A Novel Acetylcholinesterase Inhibitor, on Isovolumetric Bladder Contractions in Rats and Guinea Pigs", The 10 <sup>th</sup> Nihonhainyoukinougakkai Program Abstract, July 2003, page 162 with English translation.
	AL	T. Doi et al., "Effects of Tak-802, An Acetylcholinesterase Inhibitor, on Bladder Functions", Nihonhinyoukikagakkai, Vol. 95, No. 2, March 2004, page 41(161) with English translation.
	AM	N. Taniguchi et al., "Effects of TAK-802 in Pressure-Flow Study with Brain-Removed Cats", Nihonhinyoukikagakkai, Vol. 95, No. 2, March 2004, page 292(412) with English translation.
	AN	H. Nagabukuro et al., "Effects of TAK-802, an Acetylcholinesterase Inhibitor, in a Sample of Isolated Bladder Muscle of Guinea Pigs", Nihonhinyoukikagakkai, Vol. 95, No. 2, March 2004, page 440(560) with English translation.
	AO	H. Nagabukuro et al., "Effects of TAK-802, A Novel Acetylcholinesterase Inhibitor, on Urodynamics in Guinea Pigs", The 10 <sup>th</sup> Nihonhainyoukinougakkai Program Abstract, July 2003, page 163 with English translation.

EXAMINER

DATE CONSIDERED